Volume 4.34 | Sep 3

Hematopoiesis News 4.34 September 3, 2013
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Clonal Analysis Unveils Self-Renewing Lineage-Restricted Progenitors Generated Directly from Hematopoietic Stem Cells
Using a single-cell transplantation system and marker mice, scientists found myeloid-restricted progenitors with long-term repopulating activity, which are lineage-committed to megakaryocytes, megakaryocyte-erythroid cells, or common myeloid cells in the phenotypically defined hematopoietic stem cell (HSC) compartment together with HSCs. [Cell] Abstract | Graphical Abstract
Register for Live Webinar: Customizing the Hematopoietic CFC Assay for Drug Development
PUBLICATIONS (Ranked by impact factor of the journal)

The Murine Long-Term Multi-Lineage Renewal Marrow Stem Cell Is a Cycling Cell
Although hematopoietic stem cell (HSC) cycle status has long been the subject of scrutiny, virtually all marrow stem cell research has been based on studies of highly purified HSCs. Investigators explored the cell cycle status of marrow stem cells in un-separated whole bone marrow. [Leukemia] Abstract

A Novel Role for Factor VIII and Thrombin/Par1 in Regulating Hematopoiesis and Its Interplay with the Bone Structure
Analysis of hematopoietic stem cells (HSC) in Factor VIII Knock Out (FVIII-KO) mice revealed a novel regulatory role for the coagulation cascade in hematopoiesis. Thus, HSC in FVIII-KO mice had reduced proportions of CD34low cells within LinSca+Kit+ progenitors, and exhibited reduced long term repopulating capacity as well as hyper G-CSF induced mobilization. [Blood] Abstract

Prostaglandin-Modulated Umbilical Cord Blood Hematopoietic Stem Cell Transplantation
Umbilical cord blood contains an inherently limited hematopoietic stem cell (HSC) count, which is associated with delayed time to engraftment, high graft failure rates and early mortality. 16,16 dimethyl prostaglandin E2 (dmPGE2) was previously identified to be a critical regulator of HSC homeostasis and researchers hypothesized that a brief ex vivo modulation with dmPGE2 could improve patient outcomes by increasing the “effective dose” of HSCs. [Blood] Abstract

A Specific PTPRC/CD45 Phosphorylation Event Governed by Stem Cell Chemokine CXCL12 Regulates Primitive Hematopoietic Cell Motility
A phosphoproteomics approach to the analysis of a hematopoietic progenitor cell line treated with CXCL12 and the Rac 1 and 2 inhibitor NSC23766 was employed to objectively discover novel mechanisms for regulation of stem cells in normal and malignant hematopoiesis. The proteomic datasets identified new aspects of CXCL12-mediated signaling and novel features of stem cell regulation. [Mol Cell Proteomics] Abstract

p27kip1 Maintains a Subset of Leukemia Stem Cells in the Quiescent State in Murine MLL-Leukemia
To investigate whether p27 plays a role in the pathogenesis of mixed-lineage leukemia (MLL), investigators examined the effects of p27 deletion (p27-/-) on MLL-AF9-induced murine acute myeloid leukemia (AML) development. HOXA9/MEIS1-induced, p27 wild-type (p27+/+) and p27-/- AML were studied in parallel as controls. [Mol Oncol] Abstract

Modification of Hematopoietic Stem/Progenitor Cells with CD19-Specific Chimeric Antigen Receptors as a Novel Approach for Cancer Immunotherapy
Researchers propose gene transfer to hematopoietic stem/progenitor cells as a novel approach to deliver the CD19-specific Chimeric Antigen Receptor, with potential for ensuring persistent production of effector cells of multiple lineages targeting B-lineage malignant cells. [Hum Gen Ther] Abstract

LDL Cholesterol Modulates Human CD34+ HSPCs through Effects on Proliferation and the IL-17 G-CSF Axis
In mice, high cholesterol levels mobilize hematopoietic stem/progenitor cells (HSPCs) into the bloodstream, and promote their differentiation to granulocytes and monocytes. Scientists determined how cholesterol levels affect HSPC quantity in humans. [PLoS One] Full Article


Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan plus Cyclophosphamide (Cy) versus Total-Body Irradiation plus Cy as Conditioning Regimen-A Report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Researchers performed a retrospective registry-based study comparing outcomes of patients with acute myelogenous leukemia in first or second remission after allogeneic stem-cell transplantation from sibling donors who underwent intravenous busulfan/Cy or Cy/total-body irradiation conditioning. [J Clin Oncol] Abstract

Tandem Autologous/Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs
Investigators prospectively evaluated in high risk myeloma patients the efficacy and toxicity of tandem autologous hematopoietic stem cell transplantation (auto-HSCT) followed by reduced intensity conditioning and allogeneic (allo)-HSCT with bortezomib and donor lymphocyte infusions introduction after allo-HSCT. [Exp Hematol] Abstract

[Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.
Current State of Art for Transplantation Paradigms in Peripheral T-Cell Lymphomas
The authors review the role of the current therapeutic approach to peripheral T-cell lymphomas focusing on the most recent advances in hematopoietic stem-cell transplantation. [Exp Rev Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
BioLineRx announced that an Issue Notification has been received from the United States Patent and Trademark Office for US Patent No. 8,455,450, which claims the use of BL-8040’s composition for obtaining hematopoietic precursor cells for use in bone marrow transplantation. [BiolineRx] Press Release | Patent

Stem Cell Agency Awards More than $40 Million in New Research Grants
The California Institute for Regenerative Medicine’s governing board, the Independent Citizens Oversight Committee, approved $40 million in funding for researchers at 10 institutions including Stanford, UCLA, UC San Diego, Human BioMolecular Research Institute, Cedars-Sinai Medical Center, The Gladstone Institutes, Sanford-Burnham Medical Research Institute, The Salk Institute, Numerate, Inc. and UC Irvine as part of its Early Translational IV Research awards. [California Institute for Regenerative Medicine] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Genetic Engineering of Hematopoiesis to Treat Inherited Diseases and Cancer
October 22, 2013
Boston, United States

Visit our events page to see a complete list of events in the hematopoiesis research community.
NEW Postdoctoral Opportunity in Hematopoietic Stem Cells (Albert Einstein College of Medicine [AECOM])

Postdoctoral Researcher – Hematopoietic and Malignant Stem Cells (Istanbul University Institute of Experimental Medicine)

Postdoctoral Fellow – Gene Expression and Regulation in Stem Cell Biology (University of Texas Medical School)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Postdoctoral Position – Hematopoietic Stem Cells (St. Jude Children’s Research Hospital)

Postdoctoral Position – Hematopoiesis (Lund Stem Cell Center)

Postdoctoral Appointee – Cell Cycle Regulation in Tumor Stem Cells (Rutgers University, Rutgers Cancer Institute of New Jersey)

Postdoctoral Position – Stem Cell Biology (St. Jude Children’s Research Hospital)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Hematopoiesis News: Archives | Events | Contact Us